glp-1 news today pharma The latest results from a trial of a pill form of popular medications offer enough information for the Eli Lilly to request global regulatory approval this year, the company said. https://cnn.it/4mHcjQ8 A diabetes drug. Then a

Food and Drug Administrations (FDA) decision in December 2024 to approve Zepbound (tirzepetide) as the first drug to treat sleep apnea in adults with obesity

Studies have examined gastric mucosal lesion repair, ulcer models, colitis models, and various inflammatory bowel disease analogues (PMID 17186181, PMID 38980576)

Zepbound was removed from the drug shortage list on October 2nd, and as of October 30th Wegovy/Ozempic are listed as available by the FDA

David Kendall, Zealands chief medical officer, said in a statement that petrelintide could result in weight loss comparable to GLP-1 drugs with a better patient experience, though he did not specify why